Key Takeaways:
- Accelerators connect regulatory, IP, reimbursement, and fundraising decisions to prevent costly mistakes.
- Early preparation is critical; U.S. market entry often takes 6–12 months post-program.
- Tailored mentorship with multiple experts boosts operational, clinical, and fundraising success.
- International startups need guidance on FDA, IP strategy, operations, and U.S.-specific fundraising.
- Effective partnerships focus on measurable outcomes, not just pilots or MOUs.
What do you think is the biggest value an accelerator brings to startups today?
Karina Sotnik: There’s an overwhelming amount of information available to founders today, and just as much noise. The biggest value an accelerator can bring is to cut through the noise and achieve clarity and focus in the US expansion strategy. In the US healthcare, many startups treat reimbursement, regulatory strategy, IP management, and fundraising as separate issues. In reality, they are deeply interconnected. A good accelerator helps founders understand how decisions in one area impact the others and how to sequence them correctly to avoid expensive mistakes.
Beyond operations, accelerators also help navigate market dynamics and cultural differences. But in regulated industries, connecting regulatory, IP, reimbursement, and fundraising strategy is where the real value lies.
From your perspective, what’s the toughest challenge programs like WorldUpstart face in supporting startups?
Karina Sotnik: Timing is the biggest challenge. Many companies are either too early, meaning they are still validating their concept, or they underestimate how long U.S. expansion takes. Across 93 graduated companies, we’ve seen that U.S. entry typically happens six to twelve months after completing the program.
So, when companies say they want to enter the U.S. in late 2026, they often don’t realize preparation must begin much earlier. Helping founders understand timing and preparation is one of the most important parts of our work.
What gaps in existing accelerator models led to designing your program?
Karina Sotnik: Most accelerators were built for software companies. Software scales quickly. Healthcare does not. Life sciences and medtech operate in regulated environments with long timelines and complex reimbursement systems. Many accelerators are generic, and that lack of sector specificity creates a gap.
Another gap is geographic rigidity. Some programs are tied to a specific city or physical space. But startups need to be where they will be most successful, where clinical trials, investors, and partners align with their strategy. Our model prepares companies for the entire U.S., not just one region.
Only 1 in 5 companies succeeds in expanding to the U.S., yet 43% of your alumni are actively growing there. How do you change the odds?
Karina Sotnik: Preparation changes the odds. Companies don’t fail because their science is weak. They struggle because they misunderstand regulatory timelines, reimbursement realities, or investor expectations.
Instead of relying on one or two entrepreneurs-in-residence, we work with more than 50 mentors: former pharma executives, hospital leaders, clinicians, and investors. Each startup works with multiple mentors and gains insights across regulatory, clinical, operational, and fundraising strategies.
We are equity-free and independent, which allows us to focus entirely on founder outcomes. That neutrality builds trust and enables unbiased guidance. That combination is what drives our 43% scaling rate.
What are the key challenges international startups face in the U.S.?
Karina Sotnik: One of the biggest mistake international companies make is assuming their home-country strategy can be transplanted to the U.S. The regulatory, reimbursement, and commercial environments operate very differently, and what works elsewhere often requires significant adaptation.
Another issue we frequently see is companies mistaking pilots for real traction. Running multiple pilots does not necessarily translate into revenue or scalable adoption. Similarly, some founders believe filing a patent is enough to secure their position. In the U.S., intellectual property is not just protective; it is a strategic asset that directly impacts fundraising, valuation, and competitive positioning.
A third misconception revolves around FDA clearance. Approval allows you to market a product, but it does not guarantee reimbursement or adoption. Companies often stall after clearance because commercialization planning, payer strategy, and clinical validation were not aligned early enough.
Operational complexity is another major hurdle. The U.S. functions less like a single market and more like 50 distinct ones, layered with federal regulation. Labor laws, tax structures, and compliance requirements vary significantly by state.
Finally, fundraising dynamics differ. U.S. investors expect a clear understanding of market entry strategy, capital efficiency, and risk mitigation. International companies must demonstrate that readiness while leveraging their global strengths.
What makes a partnership effective?
Karina Sotnik: Startups often get stuck in what I call the “pilot desert.” They move from pilot to pilot without converting to revenue. An effective partnership has a defined purpose. A pilot should answer specific clinical or commercial questions and lead to clear next steps. Ideally, procurement, expanded deployment, or reimbursement validation.
We encourage founders to treat early engagements as structured validation trials, not pilots for their own sake. Success criteria must be defined in advance. If it feels too easy, it’s probably noise. If it’s challenging and data-driven, it is more likely to have real traction.
Can you share success stories?
Karina Sotnik: We have many! But for the sake of time, I will give you two. First example is Alcediag, a women-led company from France that developed a biomarker for early bipolar disorder diagnosis. They are now based in Boston, FDA cleared, and have multiple products on the U.S. market.
Another is DxYourWay from the UK, focused on early STD diagnostics through mail-order testing kits. They are expanding across multiple U.S. states, working with state governments, and operating their own lab in Ohio.
Both companies demonstrate how preparation and strategic alignment translate into sustainable U.S. growth.
How does R2GConnect help?
Karina Sotnik: R2GConnect has been a strong partner for us. The quality of companies on the platform is notably high. We see fewer concept-stage startups and more companies that are genuinely U.S.-ready with traction in their home markets.
That level of screening makes a real difference. It allows us to engage with founders at the right stage for meaningful expansion and connect them with the right ecosystem partners.
R2GConnect: Thank you for this insightful and engaging conversation, Karina.
Looking to Scale Your Health Tech Startup in the U.S.?
Check out WorldUpstart’s open call for their U.S. Market Gateway Accelerator, equity-free, mentor-driven, designed to help Digital Health, Life Sciences, and MedTech startups navigate regulations, fundraising, and successful market entry.
Apply by August 2nd, 2026 here